nach oben

Current Urology Reports

Erschienen in:

01.05.2019 | Endourology (P Mucksavage and B Somani, Section Editors)

Understanding the Link Between Gut Microbiome and Urinary Stone Disease

verfasst von: Justin A. Lee, Joshua M. Stern

Erschienen in: Current Urology Reports | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

With recent advances in sequencing technologies and increasing research into the gut microbiome (GMB), studies have revealed associations between the GMB and urinary stone disease (USD). We sought to determine whether the evidence pointed towards a few specific gut bacteria or the broader GMB network is seemingly responsible for this relationship.

Recent Findings

Initially, Oxalobacter formigenes (OF) was pursued as the main link between GMB and USD given its ability to degrade oxalate in the gut. However, the latest studies consistently suggest that the entire GMB is much more likely to be involved in handling oxalate absorption and other risk factors for urinary stone formation, rather than just a few microbiota.

Summary

The GMB has complex networks that are likely involved in the pathophysiology of USD, although the causal mechanisms remain unclear. With increasing interest and research, potential modalities that act on the GMB may help to prevent incidence of USD.

Scales CD Jr, Smith AC, Hanley JM, Saigal CS. Urologic diseases in America P. Prevalence of kidney stones in the United States. Eur Urol. 2012;62(1):160–5. https://doi.org/10.1016/j.eururo.2012.03.052.CrossRefPubMedPubMedCentral

Sokolowska M, Frei R, Lunjani N, Akdis CA, O'Mahony L. Microbiome and asthma. Asthma Res Pract. 2018;4(1). https://doi.org/10.1186/s40733-017-0037-y.

Knoll RL, Forslund K, Kultima JR, Meyer CU, Kullmer U, Sunagawa S, et al. Gut microbiota differs between children with inflammatory bowel disease and healthy siblings in taxonomic and functional composition: a metagenomic analysis. Am J Physiol Gastrointest Liver Physiol. 2017;312(4):G327–G39. https://doi.org/10.1152/ajpgi.00293.2016.CrossRefPubMed

Butto LF, Haller D. Dysbiosis in Crohn’s disease - joint action of stochastic injuries and focal inflammation in the gut. Gut Microbes. 2017;8(1):53–8. https://doi.org/10.1080/19490976.2016.1270810.CrossRefPubMedPubMedCentral

Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011;472(7341):57–63. https://doi.org/10.1038/nature09922.CrossRefPubMedPubMedCentral

Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31. https://doi.org/10.1038/nature05414.CrossRefPubMed

Everard A, Cani PD. Diabetes, obesity and gut microbiota. Best Pract Res Clin Gastroenterol. 2013;27(1):73–83. https://doi.org/10.1016/j.bpg.2013.03.007.CrossRefPubMed

Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5(2):e9085. https://doi.org/10.1371/journal.pone.0009085.CrossRefPubMedPubMedCentral

Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012;143(4):913–6 e7. https://doi.org/10.1053/j.gastro.2012.06.031.CrossRefPubMed

10.

Hess B. Metabolic syndrome, obesity and kidney stones. Arab J Urol. 2012;10(3):258–64. https://doi.org/10.1016/j.aju.2012.04.005.CrossRefPubMedPubMedCentral

11.

Lee JA, Abramowitz MK, Kipperman N, Drzewiecki BA, Melamed ML, Stern JM. Exploring the association of asthma with urinary stone disease: results from the National Health and Nutrition Examination Survey 2007-2014. Eur Urol Focus. 2018. https://doi.org/10.1016/j.euf.2018.07.035.

12.

Siener R, Bangen U, Sidhu H, Honow R, von Unruh G, Hesse A. The role of Oxalobacter formigenes colonization in calcium oxalate stone disease. Kidney Int. 2013;83(6):1144–9. https://doi.org/10.1038/ki.2013.104.CrossRefPubMed

13.

Holmes RP, Knight J, Assimos DG. Lowering urinary oxalate excretion to decrease calcium oxalate stone disease. Urolithiasis. 2016;44(1):27–32. https://doi.org/10.1007/s00240-015-0839-4.CrossRefPubMed

14.

Kartha GK, Li I, Comhair S, Erzurum SC, Monga M. Co-occurrence of asthma and nephrolithiasis in children. PLoS One. 2017;12(1):e0168813. https://doi.org/10.1371/journal.pone.0168813.CrossRefPubMedPubMedCentral

15.

• Miller AW, Dale C, Dearing MD. Microbiota diversification and crash induced by dietary oxalate in the mammalian herbivore Neotoma albigula. mSphere. 2017;2(5). https://doi.org/10.1128/mSphere.00428-17 An experimental study of metabolism of dietary oxalate in an animal model. This study examined the stability of diverse microbiomes in relation to metabolism of dietary oxalate. Its findings suggested that more diverse networks of microbiota were resistant to destabilization.

16.

Mehta M, Goldfarb DS, Nazzal L. The role of the microbiome in kidney stone formation. Int J Surg. 2016;36(Pt D):607–12. https://doi.org/10.1016/j.ijsu.2016.11.024.CrossRefPubMedPubMedCentral

17.

Stern JM, Moazami S, Qiu Y, Kurland I, Chen Z, Agalliu I, et al. Evidence for a distinct gut microbiome in kidney stone formers compared to non-stone formers. Urolithiasis. 2016;44(5):399–407. https://doi.org/10.1007/s00240-016-0882-9.CrossRefPubMedPubMedCentral

18.

Tropini C, Earle KA, Huang KC, Sonnenburg JL. The gut microbiome: connecting spatial organization to function. Cell Host Microbe. 2017;21(4):433–42. https://doi.org/10.1016/j.chom.2017.03.010.CrossRefPubMedPubMedCentral

19.

• Tang R, Jiang Y, Tan A, Ye J, Xian X, Xie Y, et al. 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones. Urolithiasis. 2018;46(6):503–14. https://doi.org/10.1007/s00240-018-1037-y This study looked at 13 stone formers with 13 healthy matched controls demonstrated decreased beta diversity amongst stone formers suggesting a unique profile for this cohort compared to controls. CrossRefPubMed

20.

• Ticinesi A, Milani C, Guerra A, Allegri F, Lauretani F, Nouvenne A, et al. Understanding the gut-kidney axis in nephrolithiasis: an analysis of the gut microbiota composition and functionality of stone formers. Gut. 2018;67:2097–106. https://doi.org/10.1136/gutjnl-2017-315734. This study of stool samples from 52 stone formers and 48 controls discovered that the abundance of five microbial taxa was associated with 24-h oxalate excretion, which further points towards a direct role for complex microbiota networks in the pathogenesis of stone formation.CrossRefPubMed

21.

Prien EL, Prien EL Jr. Composition and structure of urinary stone. Am J Med. 1968;45(5):654–72.CrossRefPubMed

22.

Szendroi A, Torde A, Vargha J, Banfi G, Horvath A, Horvath C, et al. Role of the diet in urinary stone formation and prevalence. Orv Hetil. 2017;158(22):851–5. https://doi.org/10.1556/650.2017.30747. CrossRefPubMed

23.

Knight J, Assimos DG, Callahan MF, Holmes RP. Metabolism of primed, constant infusions of [1,2-(1)(3)C(2)] glycine and [1-(1)(3)C(1)] phenylalanine to urinary oxalateMetabolism. 2011;60(7):950–6. https://doi.org/10.1016/j.metabol.2010.09.002.CrossRefPubMed

24.

Freel RW, Whittamore JM, Hatch M. Transcellular oxalate and Cl-absorption in mouse intestine is mediated by the DRA anion exchanger Slc26a3, and DRA deletion decreases urinary oxalate. Am J Physiol Gastrointest Liver Physiol. 2013;305(7):G520–7. https://doi.org/10.1152/ajpgi.00167.2013.CrossRefPubMedPubMedCentral

25.

Knauf F, Ko N, Jiang Z, Robertson WG, Van Itallie CM, Anderson JM, et al. Net intestinal transport of oxalate reflects passive absorption and SLC26A6-mediated secretion. J Am Soc Nephrol. 2011;22(12):2247–55. https://doi.org/10.1681/asn.2011040433.CrossRefPubMedPubMedCentral

26.

Jiang Z, Asplin JR, Evan AP, Rajendran VM, Velazquez H, Nottoli TP, et al. Calcium oxalate urolithiasis in mice lacking anion transporter Slc26a6. Nat Genet. 2006;38(4):474–8. https://doi.org/10.1038/ng1762.CrossRefPubMed

27.

Yao JJ, Bai S, Karnauskas AJ, Bushinsky DA, Favus MJ. Regulation of renal calcium receptor gene expression by 1,25-dihydroxyvitamin D3 in genetic hypercalciuric stone-forming rats. J Am Soc Nephrol. 2005;16(5):1300–8. https://doi.org/10.1681/asn.2004110991.CrossRefPubMed

28.

Hatch M, Cornelius J, Allison M, Sidhu H, Peck A, Freel RW. Oxalobacter sp. reduces urinary oxalate excretion by promoting enteric oxalate secretion. Kidney Int. 2006;69(4):691–8. https://doi.org/10.1038/sj.ki.5000162.CrossRefPubMed

29.

Arvans D, Jung YC, Antonopoulos D, Koval J, Granja I, Bashir M, et al. Oxalobacter formigenes-derived bioactive factors stimulate oxalate transport by intestinal epithelial cells. J Am Soc Nephrol. 2017;28(3):876–87. https://doi.org/10.1681/ASN.2016020132.CrossRefPubMed

30.

Hatch M, Gjymishka A, Salido EC, Allison MJ, Freel RW. Enteric oxalate elimination is induced and oxalate is normalized in a mouse model of primary hyperoxaluria following intestinal colonization with Oxalobacter. Am J Physiol Gastrointest Liver Physiol. 2011;300(3):G461–9. https://doi.org/10.1152/ajpgi.00434.2010.CrossRefPubMed

31.

Kaufman DW, Kelly JP, Curhan GC, Anderson TE, Dretler SP, Preminger GM, et al. Oxalobacter formigenes may reduce the risk of calcium oxalate kidney stones. J Am Soc Nephrol. 2008;19(6):1197–203. https://doi.org/10.1681/ASN.2007101058.CrossRefPubMedPubMedCentral

32.

•• Milliner D, Hoppe B, Groothoff J. A randomised Phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria. Urolithiasis. 2017. https://doi.org/10.1007/s00240-017-0998-6 A phase 3 clinical trial of 36 patients that demonstrated the use of oral Oxalobacter formigenes was not associated with changes in urinary oxalate excretion. This was the first large study to show that OF alone was not capable of inducing changes in urinary oxalate excretion in a meaningful way. CrossRefPubMedPubMedCentral

33.

• Caudarella R, Vescini F. Urinary citrate and renal stone disease: the preventive role of alkali citrate treatment. Arch Ital Urol Androl. 2009;81(3):182–7 This study focused on the lack of efficacy of probiotics containing oxalate-degrading bacteria, rather suggesting a robust network of bacteria that work together in regulating oxalate degradation.PubMed

34.

Batagello CA, Monga M, Miller AW. Calcium oxalate urolithiasis: a case of missing microbes? J Endourol. 2018;32:995–1005. https://doi.org/10.1089/end.2018.0294.CrossRefPubMed

35.

Liu M, Koh H, Kurtz ZD, Battaglia T, PeBenito A, Li H, et al. Oxalobacter formigenes-associated host features and microbial community structures examined using the American Gut Project. Microbiome. 2017;5(1):108. https://doi.org/10.1186/s40168-017-0316-0.CrossRefPubMedPubMedCentral

36.

Soucie JM, Thun MJ, Coates RJ, McClellan W, Austin H. Demographic and geographic variability of kidney stones in the United States. Kidney Int. 1994;46(3):893–9.CrossRefPubMed

37.

Gupta S, Allen-Vercoe E, Petrof EO. Fecal microbiota transplantation: in perspective. Ther Adv Gastroenterol. 2016;9(2):229–39. https://doi.org/10.1177/1756283X15607414.CrossRef

38.

Marotz CA, Zarrinpar A. Treating obesity and metabolic syndrome with fecal microbiota transplantation. Yale J Biol Med. 2016;89(3):383–8.PubMedPubMedCentral

39.

Lopez J, Grinspan A. Fecal microbiota transplantation for inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2016;12(6):374–9.

40.

•• Stern J, Burk R, Schoenfeld D, Davies K, Asplin J, Suadicani S. Fecal transplant modifies urine chemistry risk factors for urinary stone disease. Phys Rep. 2019; This study demonstrated that the ability of fecal transplants of the whole gut microbiome could modulate urinary parameters related to stone formation in an animal model.

41.

Miller AW, Oakeson KF, Dale C, Dearing MD. Microbial community transplant results in increased and long-term oxalate degradation. Microb Ecol. 2016;72(2):470–8. https://doi.org/10.1007/s00248-016-0800-2.CrossRefPubMedPubMedCentral

42.

Lieske JC. Probiotics for prevention of urinary stones. Ann Transl Med. 2017;5(2):29. https://doi.org/10.21037/atm.2016.11.86.CrossRefPubMedPubMedCentral

43.

Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A. 2011;108(Suppl 1):4554–61. https://doi.org/10.1073/pnas.1000087107.CrossRefPubMed

44.

Kharlamb V, Schelker J, Francois F, Jiang J, Holmes RP, Goldfarb DS. Oral antibiotic treatment of Helicobacter pylori leads to persistently reduced intestinal colonization rates with Oxalobacter formigenes. J Endourol. 2011;25(11):1781–5. https://doi.org/10.1089/end.2011.0243.CrossRefPubMedPubMedCentral

45.

Tasian GE, Jemielita T, Goldfarb DS, Copelovitch L, Gerber JS, Wu Q, et al. Oral antibiotic exposure and kidney stone disease. J Am Soc Nephrol. 2018;29(6):1731–40. https://doi.org/10.1681/ASN.2017111213.CrossRefPubMedPubMedCentral

46.

Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6(11):e280. https://doi.org/10.1371/journal.pbio.0060280.CrossRefPubMedPubMedCentral

47.

Arora HC, Eng C, Shoskes DA. Gut microbiome and chronic prostatitis/chronic pelvic pain syndrome. Ann Transl Med. 2017;5(2):30. https://doi.org/10.21037/atm.2016.12.32.CrossRefPubMedPubMedCentral

48.

Marinkovic SP, Moldwin R, Gillen LM, Stanton SL. The management of interstitial cystitis or painful bladder syndrome in women. BMJ. 2009;339:b2707. https://doi.org/10.1136/bmj.b2707.CrossRefPubMed

49.

Warren JW, Brown V, Jacobs S, Horne L, Langenberg P, Greenberg P. Urinary tract infection and inflammation at onset of interstitial cystitis/painful bladder syndrome. Urology. 2008;71(6):1085–90. https://doi.org/10.1016/j.urology.2007.12.091.CrossRefPubMed

50.

Burkhard FC, Blick N, Hochreiter WW, Studer UE. Urinary urgency and frequency, and chronic urethral and/or pelvic pain in females. Can doxycycline help? J Urol. 2004;172(1):232–5. https://doi.org/10.1097/01.ju.0000128698.93305.2e.CrossRefPubMed

51.

Siddiqui H, Lagesen K, Nederbragt AJ, Jeansson SL, Jakobsen KS. Alterations of microbiota in urine from women with interstitial cystitis. BMC Microbiol. 2012;12:205. https://doi.org/10.1186/1471-2180-12-205.CrossRefPubMedPubMedCentral

52.

Shoskes DA, Wang H, Polackwich AS, Tucky B, Altemus J, Eng C. Analysis of gut microbiome reveals significant differences between men with chronic prostatitis/chronic pelvic pain syndrome and controls. J Urol. 2016;196(2):435–41. https://doi.org/10.1016/j.juro.2016.02.2959.CrossRefPubMed

53.

Fouts DE, Pieper R, Szpakowski S, Pohl H, Knoblach S, Suh MJ, et al. Integrated next-generation sequencing of 16S rDNA and metaproteomics differentiate the healthy urine microbiome from asymptomatic bacteriuria in neuropathic bladder associated with spinal cord injury. J Transl Med. 2012;10:174. https://doi.org/10.1186/1479-5876-10-174.CrossRefPubMedPubMedCentral

54.

Pearce MM, Hilt EE, Rosenfeld AB, Zilliox MJ, Thomas-White K, Fok C, et al. The female urinary microbiome: a comparison of women with and without urgency urinary incontinence. MBio. 2014;5(4):e01283–14. https://doi.org/10.1128/mBio.01283-14.CrossRefPubMedPubMedCentral

55.

Nelson DE, Van Der Pol B, Dong Q, Revanna KV, Fan B, Easwaran S, et al. Characteristic male urine microbiomes associate with asymptomatic sexually transmitted infection. PLoS One. 2010;5(11):e14116. https://doi.org/10.1371/journal.pone.0014116.CrossRefPubMedPubMedCentral

56.

Barr-Beare E, Saxena V, Hilt EE, Thomas-White K, Schober M, Li B, et al. The interaction between Enterobacteriaceae and calcium oxalate deposits. PLoS One. 2015;10(10):e0139575. https://doi.org/10.1371/journal.pone.0139575.CrossRefPubMedPubMedCentral

57.

Schwaderer AL, Wolfe AJ. The association between bacteria and urinary stones. Ann Transl Med. 2017;5(2):32. https://doi.org/10.21037/atm.2016.11.73.CrossRefPubMedPubMedCentral

58.

De Ferrari ME, Macaluso M, Brunati C, Pozzoli R, Colussi G. Hypocitraturia and Ureaplasma urealyticum urinary tract infection in patients with idiopathic calcium nephrolithiasis. Nephrol Dial Transplant. 1996;11(6):1185.CrossRefPubMed

Titel: Understanding the Link Between Gut Microbiome and Urinary Stone Disease
verfasst von: Justin A. Lee
Joshua M. Stern
Publikationsdatum: 01.05.2019
Verlag: Springer US
Erschienen in: Current Urology Reports / Ausgabe 5/2019
Print ISSN: 1527-2737
Elektronische ISSN: 1534-6285
DOI: https://doi.org/10.1007/s11934-019-0882-8

Neu im Fachgebiet Urologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

Stufenschema weist Prostatakarzinom zuverlässig nach

22.04.2024 Prostatakarzinom Nachrichten

Erst PSA-Test, dann Kallikrein-Score, schließlich MRT und Biopsie – ein vierstufiges Screening-Schema kann die Zahl der unnötigen Prostatabiopsien erheblich reduzieren: Die Hälfte der Männer, die in einer finnischen Studie eine Biopsie benötigten, hatte einen hochgradigen Tumor.

Harnwegsinfektprophylaxe: Es geht auch ohne Antibiotika

20.04.2024 EAU 2024 Kongressbericht

Beim chronischen Harnwegsinfekt bei Frauen wird bisher meist eine Antibiotikaprophylaxe eingesetzt. Angesichts der zunehmenden Antibiotikaresistenz erweist sich das Antiseptikum Methenamin-Hippurat als vielversprechende Alternative, so die Auswertung einer randomisierten kontrollierten Studie.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2019

Correction to: Enhanced Endoscopy in Bladder Cancer

Management of Occult Urinary Incontinence with Prolapse Surgery

Patient-Reported Outcome Measures (PROMs) in Pelvic Floor Disorders

Knowledge Gaps in Urologic Care of Female Spinal Cord Injury Patients